CannTrust to Hold Third Quarter 2018 Financial Results Conference Call

VAUGHAN, Ontario, Nov. 10, 2018 /PRNewswire/ -- CannTrust Holdings Inc. ("CannTrust" or the "Company") (TSX: TRST), one of Canada's leading and most trusted licensed producers of cannabis, plans to release its financial results for the third quarter ended September 30, 2018 on Wednesday, November 14, 2018 after market close. The Company will host a conference call the same day at 5:00 p.m. ET to discuss its third quarter financial results and provide investors with key business highlights. The call will be hosted by Peter Aceto, Chief Executive Officer and Ian Abramowitz, Chief Financial Officer.

CONFERENCE CALL DETAILS

Date: November 14, 2018 | Time: 5:00 p.m. EST

Participant Dial-in: ([phone] or ([phone]

Conference ID: 84565275

Listen to webcast:

 https://event.on24.com/wcc/r/1879830/2F65191CDFE1A4A23146693D182FC3DD 

For more information on CannTrust, please visit https://canntrust.ca/.

About CannTrust

CannTrust - a front-runner in the cannabis industry, a federally regulated licensed producer and proudly a Canadian company - is leading the Canadian and global market in producing standardized cannabis products. Started as Canada's only pharmacist-founded medical cannabis producer, CannTrust brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust currently operates its 450,000 sq. ft. Niagara Perpetual Harvest Facility. The 600,000 sq. ft. greenhouse expansion has begun and is fully funded. The industry's broadest product portfolio is prepared and packaged at the 60,000 sq. ft. manufacturing Centre of excellence in Vaughan, Ontario.

CannTrust is ready for Cannabis 2.0, and is currently developing new products for future verticals that span the medical, recreational, beauty, wellness and pet markets. CannTrust is committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Its product development teams along with its exclusive global pharmaceutical partner, Apotex Inc., are diligently innovating and developing products that will make it easier for patients to use medical cannabis. CannTrust supports ongoing patient education about medical cannabis and has a compassionate use program to support patients with financial needs.